- Home
- MNSB vs MNOV Comparison
MNSB vs MNOV Comparison
Compare MNSB & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNSB | MNOV |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 137.8M |
| IPO Year | 2017 | 2004 |
Fundamental Metrics
Financial Performance| Metric | MNSB | MNOV |
|---|---|---|
| Price | $22.10 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 32.5K | ★ 57.5K |
| Earning Date | 10-26-2026 | 11-16-2026 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | ★ 210.00 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $135,615,000.00 | $2,360,807.00 |
| Revenue This Year | N/A | $78.20 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.91 | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $17.97 | $1.22 |
| 52 Week High | $25.87 | $3.90 |
Technical Indicators
Market Signals| Indicator | MNSB | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | 42.72 |
| Support Level | $21.32 | $1.28 |
| Resistance Level | $25.32 | $1.54 |
| Average True Range (ATR) | 0.80 | 0.06 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 28.59 | 51.25 |
Price Performance
Historical ComparisonAbout MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.